Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals announced inducement equity grants to nine new non-officer employees totaling 24,250 share options and 14,250 RSUs, effective October 29, 2026. The options carry a $37.54 exercise price equal to the grant-date close and vest over four years under the company's 2025 Inducement Equity Incentive Plan.
Key figures
- New employees
- 9
- Exercise price
- 37.54
- Inducement rsus
- 14250
- Inducement options
- 24250
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.